Make an enquiry
Refer a patient
Patient Portal
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
2024-08-27T07:34:32.303Z

MAHOGANY

MAHOGANY
Lymphoma

A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

Trial overview

Clinical Area

Haemotology

Disease / Condition

Lymphoma

Study Phase

III

Trial Identifiers

NCT05100862

 

https://www.clinicaltrials.gov/study/NCT05100862

GenesisCare Location(s)

GenesisCare North Adelaide

GenesisCare North Adelaide :::
Principal Investigator(s)

Dr Wilfred Jaksic

 

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.